Rotarix Oral Suspension (Tube)

Šalis: Singapūras

kalba: anglų

Šaltinis: HSA (Health Sciences Authority)

Veiklioji medžiaga:

HUMAN ROTAVIRUS, LIVE, ATTENUATED, RIX 4414 STRAIN

Prieinama:

GLAXOSMITHKLINE PTE LTD

ATC kodas:

J07BH01

Dozė:

Not less than 10⁶ CCID₅₀/dose (1.5 ml)

Vaisto forma:

SUSPENSION

Sudėtis:

HUMAN ROTAVIRUS, LIVE, ATTENUATED, RIX 4414 STRAIN Not less than 10⁶ CCID₅₀/dose (1.5 ml)

Vartojimo būdas:

ORAL

Recepto tipas:

Prescription Only

Pagaminta:

GlaxoSmithKline Biologicals s.a.

Autorizacija statusas:

ACTIVE

Leidimo data:

2010-06-01

Pakuotės lapelis

- 1 - 
ROTARIX
TM

ROTAVIRUS VACCINE 
QUALITATIVE AND QUANTITATIVE COMPOSITION 
1 dose (1.5 ml) contains: 
Live attenuated human rotavirus RIX4414 strain* of the
G1P[8] type:  
not less than 10
6.0

CCID
50 

*Produced on Vero cells  

PHARMACEUTICAL FORM 
ORAL suspension. 
The vaccine is a clear and colourless liquid. 

CLINICAL PARTICULARS 
INDICATIONS 
_ROTARIX_
_TM_
 is indicated for the active immunisation of infants from
the age of 6 weeks for 
prevention of gastro-enteritis due to rotavirus infection
(_see sections Dosage and _
_Administation and Pharmacodynamics_).   

DOSAGE AND ADMINISTRATION 

POSOLOGY 
The vaccination course consists of two doses. The first
dose may be administered from the 
age of 6 weeks. There should be an interval of at least 4 weeks
between doses. The 
vaccination course should preferably be given before 16 weeks of
age, but must be completed 
by the age of 24 weeks.  
In clinical trials, spitting or regurgitation of the vaccine has
rarely been observed and, under 
such circumstances, a replacement dose was not given. However, in
the unlikely event that an 
infant spits out or regurgitates most of the vaccine dose,
a single replacement dose may be 
given at the same vaccination visit. 
It  is  recommended  that  infants  who  receive  a  first  dose  of  _ROTARIX_
_TM_
  complete  the  2-dose 
regimen  with  _ROTARIX_
_TM_
.  There  are  no  data  on  safety,  immunogenicity  or  efficacy  when 
_ROTARIX_
_TM_
 is administered for the first dose and another rotavirus vaccine is administered for 
the second dose or vice versa. 

METHOD OF ADMINISTRATION 
_ROTARIX_
_TM_
 is for ORAL use only. Administer the entire content (1.5 mL) of the tube ORALLY 
on the inside of the cheek. 
_ROTARIX_
_TM_
 SHOULD UNDER NO CIRCUMSTANCES BE INJECTED. 

There are no restrictions on the 

Prekės savybės

- 1 -
ROTARIX
ROTAVIRUS VACCINE
ORAL SUSPENSION
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 dose (1.5 ml) contains:
Live attenuated human rotavirus RIX4414 strain* of the G1P[8] type:
not less than 10
6.0
CCID
50
*Produced on Vero cells
The vaccine is a clear and colourless liquid.
CLINICAL INFORMATION
INDICATIONS
_ROTARIX_ is indicated for the active immunisation of infants from the
age of 6 weeks for
prevention of gastro-enteritis due to rotavirus infection (_see
sections Dosage and _
_Administration, Warnings and Precautions and Pharmacodynamics_).
DOSAGE AND ADMINISTRATION
POSOLOGY
The vaccination course consists of two doses. The first dose may be
administered from the
age of 6 weeks. There should be an interval of at least 4 weeks
between doses. The
vaccination course should preferably be given before 16 weeks of age,
but must be completed
by the age of 24 weeks.
In clinical trials, spitting or regurgitation of the vaccine has
rarely been observed and, under
such circumstances, a replacement dose was not given. However, in the
unlikely event that an
infant spits out or regurgitates most of the vaccine dose, a single
replacement dose may be
given at the same vaccination visit.
It is recommended that infants who receive a first dose of _ ROTARIX_
complete the 2-dose
regimen with _ROTARIX_. There are no data on safety, immunogenicity or
efficacy when _ROTARIX_
is administered for the first dose and another rotavirus vaccine is
administered for the second
dose or vice versa.
METHOD OF ADMINISTRATION
_ROTARIX_ is for ORAL use only. Administer the entire content (1.5 mL)
of the tube ORALLY on
the inside of the cheek.
_ _
_ROTARIX_ SHOULD UNDER NO CIRCUMSTANCES BE INJECTED.
There are no restrictions on the infant’s consumption of food or
liquid, including breast-milk,
either before or after vaccination.
- 2 -
Based on evidence generated in clinical trials, breast-feeding does
not reduce the protection
against rotavirus gastro-enteritis afforded by _ROTARIX_. Therefore,
breast-feeding may be
continued during the v